Exploring QSARs with Extended Topochemical Atom (ETA) indices for modeling chemical and drug toxicity

Current Pharmaceutical Design

Volumn 16, Issue 24, 2010, Pages 2625-2639

  Roy, Kunal ^a   Ghosh, Gopinath ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

ETA; QSAR; QSPR; QSTR; TAU; Toxicity; VEM

Indexed keywords

ANTIBIOTIC AGENT; BENZENE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOXYLIC ACID DERIVATIVE; CORTICOSTEROID; DIGOXIN; DRUG METABOLITE; NITROBENZENE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; ORGANIC COMPOUND; PHENOL DERIVATIVE; POLYCHLORINATED BIPHENYL;

ARTICLE; CONTROLLED STUDY; ECOTOXICITY; ENVIRONMENTAL PROTECTION; HUMAN; MOLECULAR MODEL; MULTIPLE CHEMICAL SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STRUCTURE PROPERTY RELATION; STATISTICAL ANALYSIS; TOXICITY; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

DRUG TOXICITY; FORECASTING; HUMANS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RISK ASSESSMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77957967208     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210792389270     Document Type: Article

References (112)

1. Sanderson H, Johnson DJ, Reitsma T, Brain RA, Wilson CJ, Solomon KR. Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul Toxicol Pharmacol 2004; 39: 158-83.
2. th ed. New York: McGraw-Hill 2001; pp. 83-104.
3. Gribaldo L. Haematotoxicology: scientific basis and regulatory aspects. Altern Lab Anim 2002; 30(2): 111-13.
4. Blaauboer BJ. The necessity of biokinetic information in the interpretation of in vitro toxicity data. Altern Lab Anim 2002; 30: 85-91.
5. th ed. 1999; pp. 69-70.
6. http://www.epa.gov/risk/index.htm
7. Zurlo J, Rudacille D, Goldberg AM. Animal and alternatives in testing: history, science, and ethics. NY: Mary Ann Liebert Inc. 1994.
8. Greenburg MI, Phillips SD. A brief history of occupational, industrial and environmental toxicology. Occupational, Industrial and Environmental Toxicology. In: Greenberg MI, Hamilton RJ, Phillips SD, Eds. Philadelphia: Mosby 2003; pp. 2-5.
9. Langley G. Acute toxicity testing without animals "more scientific and Less of a Gamble". London: European Coalition to End Animal Experiments (ECEAE) 2005.
10. Stenberg M, Andersson PL. Selection of non-dioxin-like PCBs for in vitro testing on the basis of environmental abundance and molecular structure. Chemosphere 2008; 71: 1909-15.
11. Ahlborg UG, Brouwer A, Fingerhut MA, et al. Impact of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls on human and environmental health, with special emphasis on application of the toxic equivalency factor concept. Eur J Pharmacol 1992; 228: 179-99.
12. DiMasi JA, Brown JS, Lasagana L. An analysis of regulatory review times of supplemental indications for already-approved drugs: 1989-1994. Drug Information J 1996; 30: 315-37.
13. Rahman SZ, Khan RA, Gupta V, Uddin M. Pharmacoenvironmentology-a component of pharmacovigilance. Environ Health 2007; 6: 20.
14. Lefebvre P. The uvea and crystalline lens: toxicity of new medications. Bull Soc Belge Ophtalmol 2007; 304: 133-44.
15. Wollenberger L, Halling-Sørensen B, Kusk KO. Acute and chronic toxicity of veterinary antibiotics to Daphnia magna. Chemosphere 2000; 40: 723-30.
16. Leclercq M, Mathieu O, Gomez E, Casellas C, Fenet H, Hillaire-Buys D. Presence and fate of carbamazepine, oxcarbazepine, and seven of their metabolites at wastewater treatment plants. Arch Environ Contam Toxicol 2009; 56: 408-15.
17. Stumpf M, Ternes TA, Wilken RD, Rodrigues SV, Baumann W. Polar drug residues in sewage and natural waters in the state of Rio de Janeiro, Brazil. Sci Total Environ 1999; 225: 135-41.
18. Jones OAH, Voulvoulis N, Lester JN. Human pharmaceuticals in the aquatic environment: a review. Environ Technol 2001; 22: 1383-94.
19. Halling-Sørensen B, Nors Nielsen S, Lanzky PF, Ingerslev F, Holten Lützhøft HC, Jørgensen SE. Occurrence, fate and effects of pharmaceutical substances in the environment-a review. Chemosphere 1998; 36: 357-93.
20. Richardson ML, Bowron JM. The fate of pharmaceutical chemicals in the aquatic environment. J Pharm Pharmacol 1985; 37: 1-12.
21. Seiler JP. Pharmacodynamic activity of drugs and ecotoxicology-can the two be connected?. Toxicol Lett 2002; 131: 105-15.
22. Leff E. It is imperative to stop environmental degradation. Demos 1990; 3: 25-6.
23. Elvers KT, Wright SJL. Antibacterial activity of the antiinflammatory compound ibuprofen. Lett Appl Microbiol 1995; 20: 82-4.
24. Kummerer K. Pharmaceuticals in the environment: sources, fate, effects and risks. Berlin: Springer-Verlag 2001.
25. Smith SR. Organic contaminants in sewage sludge (biosolids) and their significance for agricultural recycling. Philos Transact A Math Phys Eng Sci 2009; 367: 4005-41.
26. Zwiener C, Frimmel FH. Short-term tests with a pilot sewage plant and biofilm reactors for the biological degradation of the pharmaceutical compounds clofibric acid, ibuprofen, and diclofenac. Sci Total Environ 2003; 309: 201-11.
27. Daughton CG, Ternes TA. Pharmaceuticals and personal care products in the environment: agents of subtle change. Environ Health Perspect 1999; 107: 907-42.
28. Nawaz MS, Erickson BD, Khan AA, et al. Human health impact and regulatory issues involving antimicrobial resistance in the food animal production environment. Regul Res Perspect 2001; 1: 1-10.
29. Hu D, Coats JR. Laboratory evaluation of mobility and sorption for the veterinary antibiotic, tylosin, in agricultural soils. J Environ Monit 2009; 11: 1634-8.
30. European Commission. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Office for Official Publications of the European Communities (OPOCE). Off J Eur Union 2006; L 396/1 of 30.12.2006. [http://publications.europa.eu].
31. Straub JO. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guide-line/discussion paper of January 2001. Toxicol Lett 2002; 131: 137-43.
32. Christensen FM. Pharmaceuticals in the environment--a human risk. Regul Toxicol Pharm 1998; 28: 212-21.
33. EMEA 2003. Note for Guidance on Environmental Risk Assessment of Medicinal Products for Human Use. CPMP/SWP/4447/00 draft corr. 2003 Available from .
34. Pouliquen H, Delépée R, Thorin C, et al. Comparison of water, sediment, and plants for the monitoring of antibiotics: a case study on a river dedicated to fish farming. Environ Toxicol Chem 2009; 28: 496-502.
35. Heberer T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol Lett 2002; 131: 5-17.
36. Sanderson H, Johnson DJ, Wilson CJ, Brain RA, Solomon KR. Probabilistic hazard assessment of environmentally occurring pharmaceuticals toxicity to fish, daphnids and algae by ECOSAR screening. Toxicol Lett 2003; 144: 383-95.
37. Jones OAH, Voulvoulis N, Lester JN. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res 2002; 36: 5013-22.
38. Stuer-Lauridsen F, Birkved M, Hansen LP, Lutzhoft HCH, Halling-Sorensen B. Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. Chemosphere 2000; 40: 783-93.
39. EU (European Union) 1996. Note for guidance: environmental risk assessment of veterinary medical products other than GMO-containing and immunological products. London: EMEA/CVMP/ 055/96. EMEA 19996.
40. Länge R, Dietrich D. Environmental risk assessment of pharmaceutical drug substances--conceptual considerations. Toxicol Lett 2002; 131: 97-104.
41. Jørgensen SE, Halling-Sørensen B. Drugs in the environment. Chemosphere 2000; 40: 691-9.
42. Sanderson H, Johnson DJ, Reitsma T, Brain RA, Wilson CJ, Solomon KR. Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul Toxicol Pharm 2004; 39: 158-83.
43. Roy K, Sengupta C, De A U. Theoretical aspects of rational drug design - an overview. J Sci Ind Res 2001; 60: 699-716.
44. Schultz T W, Cronin MT. Essential and desirable characteristics of ecotoxicity quantitative structure-activity relationships. Environ Toxicol Chem 2003; 22: 599-607.
45. Coats E A. QSAR Challenges and Opportunities: A Commentary. http://www.netsci.org/Science/Compchem/feature13.html (last accessed on July 21, 2010).
46. Selassie CD. History of quantitative structure-activity relationships. In: Burger's medicinal chemistry and drug discovery. Abraham DJ, Ed. New York, USA: John Wiley 2003; p. 1-48.
47. Perkins R, Fang H, Tong W, Welsh WJ. Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem 2003; 22: 1666-79.
48. Walker JD, Jaworska J, Comber JHI, Schultz TW, Dearden JC. Guidelines for developing and using quantitative structure-activity relationships. Environ Toxicol Chem 2003; 22: 1653-65.
49. Yang GF, Huang F. Development of quantitative structure-activity relationships and its application in rational drug design. Curr Pharm Des 2006; 12: 4601-11.
50. Mazzatorta P, Benfenati E, Lorenzini P, Vighi M. QSAR in ecotoxicity: an overview of modern classification techniques. J Chem Inf Comput Sci 2004; 44: 105-12.
51. Baroni M, Clementi S, Cruciani C, Kettaneth-Wold M, Wold SD. D-optimal designs in QSAR. Quant Strut-Act Relat 1993; 12: 225.
52. Box GEP, Hunter WG, Hunter JS. Statistics for experimenters. New York: Wiley 1978.
53. Roy K. On some aspects of validation of predictive_quantitative structure-activity relationship models. Expert Opin Drug Discov 2007; 2: 1567-77.
54. Hansch C, Leo A. Exploring QSAR, fundamentals and applications in chemistry and biology. Washington, DC: American Chemical Society 1995; p. 580.
55. Wold S, Eriksson L. Statistical validation of QSAR results, in: Chemometric methods in molecular design. van de Waterbeemd H, Ed. USA: VCH, Weinheim 1995; pp. 312-7.
56. Debnath AK. Quantitative structure-activity relationship (QSAR): a versatile tool in drug design. In: Combinatorial library design and evaluation. Ghose AK, Viswanadhan VN, Eds. New York: Marcel Dekker, Inc. 2001; pp. 73-129.
57. Roy P, Roy K. On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008; 27: 302-13.
58. Everitt BS, Landau S, Leese M. Cluster Analysis, London: Edward Arnold 2001.
59. Clark RD, Sprous DG, Leonard JM, Höltje I HD. W Sippl; Eds. Rational approaches to drug design. Barcelona: Prous Science 2001; pp. 475-85.
60. Golbraikh A, Tropsha A. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J Comput Aided Mol Des 2002; 16: 357-69.
61. Tong W, Hong H, Xie Q, Shi L, Fang H, Perkins R. Assessing QSAR limitations - a regulatory perspective. Curr Comput Aided Drug Des 2005; 1: 195-205.
62. He L, Jurs PC. Assessing the reliability of a QSAR model's predictions. J Mol Graph Mod 2005; 23: 503-23.
63. Ghafourian T, Cronin MTD. The impact of variable selection on the modelling of oestrogenicity. SAR QSAR Environ Res 2005; 16: 171-90.
64. Tropsha A, Gramatica P, Gombar VK. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 2003; 22: 69-77.
65. Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Mod 2002; 20: 269-76.
66. Tong W, Xie Q, Hong H, Shi L, Fang H, Perkins R. Assessment of prediction confidence and domain extrapolation of two structure-activity relationship models for predicting estrogen receptor binding activity. Environ Health Perspect 2004; 112: 1249-54.
67. Hulzebos EM, Posthumus R. (Q)SARs: gatekeepers against risk on chemicals? SAR QSAR Environ Res 2003; 14: 285-316.
68. Marchini S. Aquatic effects assessment: needs and tools. Ann Ist Super Sanita 2002; 38(2): 119-29.
69. Jambhekar SS. Principles of medicinal chemistry. 4th ed, In: Foye WO, Lemke TL, Williams DA, Eds. New Delhi. B. I. Waverly Pvt. Ltd. 1995; p. 12.
70. Roy K, Roy PP. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques. Eur J Med Chem 2009; 44: 2913-22.
71. Roy PP, Roy K. QSAR studies of CYP2D6 inhibitor aryloxypro-panolamines using 2D and 3D descriptors. Chem Biol Drug Des 2009; 73: 2009. 442-55.
72. Roy PP, Paul S, Mitra I, Roy K. On two novel parameters for validation of predictive QSAR models. Molecules 2009: 14: 1660-701.
73. Mitra I, Roy PP, Kar S, Ojha P, Roy K. On further application of rm2 as a metric for validation of QSAR models. J Chemometrics 2010; 24: 22-33.
74. Roy K, Ghosh G. Introduction of extended topochemical atoms (ETA) indices in the valence electron mobile (VEM) environment as tool for QSAR QSPR studies. Internet Electron J Mol Des 2003; 2: 599-620. http://www.biochempress.com.
75. Roy K, Ghosh G. QSTR with extended topochemical atom indices. 2. Fish toxicity of substituted benzenes. J Chem Inf Comput Sci 2004; 44: 559-67.
76. Roy K, Ghosh G. QSTR with extended topochemical atom indices. 3. Toxicity of nitrobenzenes to Tetrahymena pyriformis. QSAR Comb Sci 2004; 23: 99-108.
77. Pal DK, Sengupta C, De AU. A new topochemical descriptor (TAU) in molecular connectivity concept: Part I --Aliphatic Compounds. Indian J Chem 1988; 27B: 734-9.
78. Pal DK, Sengupta C, De AU. Introduction of a novel topochemical index and exploitation of group connectivity concept to achieve predictability in QSAR and RDD. Indian J Chem 1989; 28B: 261-7.
79. Pal DK, Sengupta M, Sengupta C, De AU. QSAR with TAU (2) indices: Part I -Polymethylene primary diamines as amebicidal agents. Indian J Chem 1990; 29B: 451-4.
80. Pal DK, Purkayastha SK, Sengupta C, De AU. Quantitative structure-property relationships with TAU indices: Part I - Research octane numbers of alkane fuel molecules. Indian J Chem 1992; 31B: 109-14.
81. Roy K, Saha A. Comparative QSPR studies with molecular connectivity, molecular negentropy and TAU indices. Part I: Molecular thermochemical properties of diverse functional acyclic compounds. J Mol Model 2003; 9: 259-70.
82. Roy K, Saha A. Comparative QSPR studies with molecular connectivity, molecular negentropy and TAU Indices. Part 2: Lipid-water partition coefficient of diverse functional acyclic compounds. Internet Electron J Mol Des 2003; 2: 288-305. http://www.biochempress.com.
83. Roy K., Saha A. QSPR with TAU indices: water solubility of diverse functional acyclic compounds. Internet Electron J Mol Des 2003; 2: 475-491. http://www.biochempress.com.
84. Roy K, Chakroborty S, Ghosh CC, Saha A. QSPR with TAU indices: Molar thermochemical properties of diverse functional acyclic compounds. J Indian Chem Soc 2004; 81: 115-25.
85. Roy K, Saha A. QSPR with TAU indices: Part 5. Liquid heat capacity of diverse functional organic compounds. J Indian Chem Soc 2006; 83: 351-5.
86. Hall LH, Vaughn TA. QSAR of phenol toxicity using electrotopological state and kappa shape indices. Med Chem Res 1997; 7: 407-16.
87. Rose K, Hall LH. E-state modeling of fish toxicity independent of 3D structure information. SAR QSAR Environ Res 2003; 14: 113-29.
88. Robert D, Carbo-Dorca R. Aromatic compounds aquatic toxicity QSAR using molecular quantum similarity measures. SAR QSAR Environ Res 1999; 10: 401-22.
89. Estrada E, Uriate E. Quantitative structure activity relationships using TOPS-MODE. 1. nitrobenzene toxicity to tetrahymena pyriformis. SAR QSAR Environ Res 2002; 12: 309-24.
90. Cronin MTD, Gregory BW, Schultz TW. Quantitative structureactivity analyses of nitrobenzene toxicity totetrahymena pyriformis. Chem Res Toxicol 1998; 11: 902-8.
91. Roy K, Ghosh G. QSTR with extended topochemical atom indices. 4. modeling of the acute toxicity of phenylsulfonyl carboxylates to vibrio fischeri using principal component factor analysis and principal component regression analysis. QSAR Comb Sci 2004; 23: 526-35.
92. Roy K, Ghosh G. QSTR with extended topochemical atom indices. Part 5. Modeling of the acute toxicity of phenylsulfonyl carboxylates to Vibrio fischeri using genetic function approximation. Bioorg Med Chem 2005; 13: 1185-94.
93. Liu X, Yang Z, Wang L. CoMFA of the acute toxicity of phenylsulfonyl carboxylates to Vibrio fischeri. SAR QSAR Environ Res 2003; 14: 183-90.
94. Roy K, Ghosh G. QSTR with extended topochemical atom (ETA) indices. VI. Acute toxicity of benzene derivatives to tadpoles (Rana japonica). J Mol Model 2006; 12: 306-16.
95. Huang H, Wang X, Ou W, Zhao J, Shao Y, Wang L. Acute toxicity of benzene derivatives to the tadpoles (Rana japonica) and QSAR analyses. Chemosphere 2003; 53: 963-70.
96. Roy K, Ghosh G. QSTR with extended topochemical atom (ETA) indices. 8. QSAR for the inhibition of substituted phenols on germination rate of Cucumis sativus using chemometric tools. QSAR Comb Sci 2006; 25: 846-59.
97. Wang X, Yu J, Wang Y, Wang L. Mechanism-based quantitative structure-activity relationships for the inhibition of substituted phenols on germination rate of Cucumis sativus. Chemosphere 2002; 46: 241-50.
98. Roy K, Sanyal I. QSTR with extended topochemical atom indices. 7. QSAR of substituted benzenes to saccharomyces cerevisiae. QSAR Comb Sci 2006; 25: 359-71.
99. Liao YY, Wang LS, He YB, Yang H. Toxicity QSAR of substituted benzenes to yeast Saccharomyces cerevisiae. Bull Environ Contam Toxicol 1996; 56: 460-6.
100. Roy K, Ghosh G. QSTR with extended topochemical atom (ETA) indices. 9. Comparative QSAR for the toxicity of diverse functional organic compounds to Chlorella vulgaris using chemometric tools. Chemosphere 2007; 70: 1-12.
101. Cronin MTD, Netzeva IT, Dearden JN, Edwards R, Worgan ADP. Assessment and modeling of the toxicity of organic chemicals to chlorella vulgaris development of novel database. Chem Res Toxicol 2004; 17: 545-54.
102. Roy K, Ghosh G. QSTR with extended topochemical atom (ETA) indices. 12. QSAR for the toxicity of diverse aromatic compounds to tetrahymena pyriformis using chemometric tools. Chemosphere 2009; 77: 999-1009.
103. Schultz TW, Netzeva TI, Cronin MTD. Selection of Data Sets for QSARs: Analysis of tetrahymena toxicity from aromatic compounds. SAR QSAR Environ Res 2003; 14: 59-81.
104. Roy K, Ghosh G. QSTR with extended topochemical atom (ETA) Indices. 10. modeling of toxicity of organic chemicals to humans using different chemometric tools. Chem Biol Drug Des 2008; 5: 383-94.
105. Lessigiarska I, Worth AP, Netzeva TI, Dearden JC, Cronin MTD. Quantitative structure-activity-activity and quantitative structure-activity investigations of human and rodent toxicity. Chemosphere 2006; 65: 1878-87.
106. Roy K, Ghosh G. QSTR with extended topochemical atom (ETA) indices. 11. Comparative QSAR of acute NSAID cytotoxicity in rat hepatocytes using chemometric tools. Mol Simul 2009; 35: 648-59.
107. Siraki AG, Chevaldina T, O'Brien PJ. Application of quantitative structure-toxicity relationships for acute NSAID cytotoxicity in rat hepatocytes. Chem-Biol Interact 2005; 151: 177-91.
108. + channel blocking activity of diverse functional drugs using different chemometric tools. Mol Simul 2009; 15: 1256-68.
109. + channel blockers using GFA and hypogen techniques. J Mol Graphics Mod 2008; 26: 966-76.
110. Roy K, Sanyal I, Roy PP. QSPR of the bioconcentration factors of nonionic organic compounds in fish using extended topochemical atom (ETA) indices. SAR QSAR Environ Res 2006; 17: 563-82.
111. Sacan MT, Erdem SS, Gul AO, Balcioglu IA. QSPR study on the ioconcentration factors of nonionic organic compounds in fish by characteristic root index and semiempirical molecular descriptors. J Chem Inf Comput Sci 2004; 44: 985-92.
112. Roy K, Sanyal I, Ghosh G. QSPR of n-Octanol & water partition coefficient of nonionic organic compounds using extended topochemical atom (ETA) indices. QSAR Comb Sci 2006; 25: 629-46.